The Liver Flush Is Soap | The Angry Gut, Chapter 28

Postcholecystectomy diarrhea · workup

Postcholecystectomy Diarrhea: A Measurement-First Workup

The workup for postcholecystectomy diarrhea starts by identifying bile acid diarrhea through the bile acid assessment available via gastroenterology, before any empiric antibiotic for overgrowth, which needs a positive breath test as its trigger. A gallstone or cholecystectomy history also belongs in the selection criteria for cardiometabolic measurement.

Patients with loose stools after cholecystectomy are often treated for overgrowth without a positive test. The evidence favors identifying bile acid loss first, and gallbladder disease itself is a cardiometabolic flag.

Postcholecystectomy diarrhea is usually handled as a nuisance to live with or as small intestinal bacterial overgrowth treated on suspicion. Both responses skip a measurement. Chapter 28 of The Angry Gut, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, is summarized in the video above, The Liver Flush Is Soap, and is built around a patient given four antibiotic courses for overgrowth whose breath tests were negative each time. For a primary care or pain practice the practical content is a sequence: identify bile acid diarrhea, withhold empiric antibiotics that lack a trigger, and treat the gallbladder history as an indication for metabolic screening.

How common is bile acid diarrhea in chronic diarrhea?

At a single teaching hospital, 1,071 consecutive outpatients with chronic diarrhea were scanned, and 42.7% had bile acid diarrhea; prior cholecystectomy was one of three predictors of an abnormal result. Selection did not create the yield. Of all referrals, 61.0% carried no known risk factor, and 35.7% of that subgroup still tested positive. Positives were type II in 51.6%, type III in 36.1% and type I in 12.3%, and 33.9% were severe. Yield showed no downward trend over five years (p = 0.39) while referrals for terminal ileal Crohn’s disease or resection fell, which argues against looser ordering diluting the figure.

One constraint applies in the United States: the scan used in that cohort is not available here, so the prevalence transfers and the diagnostic route does not. Referral to gastroenterology for the bile acid assessment available locally is the practical step. None of these investigations is a Measura test.

Is SIBO common after cholecystectomy?

The intuitive model holds that losing the reservoir lets bacteria ascend. Dr. Padda taught that model, and the cohorts forced a revision. In 146 abdominal surgery patients against 30 healthy controls, overgrowth ran 37.6% versus 13.3%, yet cholecystectomy had the lowest rate at 17.1%, against 36.0% after hysterectomy and 96.2% after gastrectomy; previous gastrectomy and elevated gastrin independently predicted the hydrogen pattern. Among 265 patients with gallbladder disease and 39 controls, positivity peaked in patients with stones in situ, 40.5%, and gallstones were the only independent factor.

Two implications follow. Stasis with the organ present carries more risk than its absence, and gastrin points to failed acid control rather than lost bile after surgery. Empiric antibiotics for overgrowth need a positive test as their trigger, and repeating a course after negative breath tests treats an assumption. The pressure behind the habit is structural: a prescription can be written inside a short encounter, whereas a breath test requires patient preparation and another visit.

Why is gallbladder disease a cardiometabolic finding?

The same gallstone cohort found gallbladder disease independently associated with fatty liver and metabolic syndrome as well as overgrowth. A gallbladder that fails to empty travels with metabolic disease rather than standing alone as a mechanical fault. That makes a gallstone or cholecystectomy history a reasonable entry in selection criteria for cardiometabolic measurement, whatever the bowel complaint.

Physiology supports the association. Luminal bile salts limit endotoxin absorption: in obstructive jaundice, oral deoxycholate given to 12 patients before surgery was followed by no systemic endotoxemia and no postoperative renal impairment. In the book’s frame the gut is the first brain and the skull holds the second brain, and endotoxin crossing a depleted luminal defense is one input to metaflammation. Maldigested fat and the fat-soluble vitamins lost with it add a nutritional dimension that routine follow-up seldom documents.

Surrogates move while patients may not

The bile literature is a lesson in endpoint discipline. A randomized trial of oral ursodeoxycholic acid in 40 jaundiced patients raised bile salt concentrations and lowered portal endotoxemia, yet systemic endotoxemia, renal function, morbidity and mortality were unchanged. Pooled trials of the same drug in primary biliary cholangitis lowered alkaline phosphatase by 257 U/L without reducing mortality, 45 of 699 against 46 of 692. In a two-year trial of 100 patients already on that drug with inadequate response, complete biochemical response in the placebo add-on arm was 0%, so non-response was visible in the blood work and identifiable in advance.

Patients also arrive taking tauroursodeoxycholic acid. Its best metabolic data, in 20 obese adults at 1,750 mg daily for four weeks, showed roughly a 30% gain in hepatic and muscle insulin sensitivity with no gut or liver endpoint recorded. The workflow lesson is identical for prescriptions and supplements: record which value is expected to change and when it will be rechecked. Decisions to start, continue or stop any agent stay with the treating physician.

What Measura adds, and what it does not

Measura [Cardiometabolic and Autonomic Health Analysis] does not measure bile acids, gallbladder function, breath hydrogen or methane, or intestinal permeability; those belong to gastroenterology. It measures the terrain the gallstone data point toward:

Laboratory panels to quantify insulin resistance and lipid status in a patient whose gallbladder history flags metabolic risk.
Bioimpedance body composition to define fat and lean compartments where weight or BMI understates risk.

Findings return to the ordering physician, and reading them in clinical context is outlined in interpreting the report.

Standing orders for postcholecystectomy diarrhea

Criteria only hold when they run without anyone remembering them. A gallstone or cholecystectomy history, chronic diarrhea with prior empiric antibiotics, or known fatty liver can each trigger metabolic measurement through standing orders. Insulin resistance and body composition documented at the wellness visit give a baseline and a repeat interval, as described in annual wellness visit integration. The patient-facing version is bile acid malabsorption after gallbladder surgery; bile as a signaling molecule is covered in the bile mechanism post; barrier repair follows in intestinal permeability testing; and every study cited is set out with its limits in the Chapter 28 companion.

Frequently asked questions

Should diarrhea after cholecystectomy be treated empirically as SIBO?

Not without a positive test. In surgical cohorts, overgrowth was least frequent after cholecystectomy, at 17.1%, and bile acid diarrhea was found in 42.7% of outpatients referred for chronic diarrhea, with prior cholecystectomy a predictor. Repeating antibiotics after negative breath tests adds exposure without a diagnosis. The broader case for measuring before managing is set out in clinical rationale.

Is bile acid testing part of the Measura protocol?

No. Bile acid assessment, gallbladder imaging and breath testing are gastroenterology investigations performed elsewhere. Measura measures the metabolic terrain that gallbladder disease travels with, through laboratory panels and body composition, and returns findings to the ordering physician. How those measures are used across practice types is described in specialty applications.

Why screen patients with gallstones for metabolic disease?

In 265 patients with gallbladder disease, the disease was independently associated with fatty liver and metabolic syndrome. A cholecystectomy or gallstone history is therefore a documented marker of metabolic risk that is already in the chart. Measuring insulin resistance and body composition converts that marker into a baseline with a repeat interval. Framing it as written criteria is covered in making screening reproducible.

How should supplement use be handled when patients bring TUDCA or milk thistle?

Document the agent and the value it is expected to change. Pooled milk thistle trials lowered AST and ALT but had no effect on alkaline phosphatase and none at a BMI of 30 or above; tauroursodeoxycholic acid trials measured insulin action and immune cells, not bile flow. No agent has been shown to raise measured bile flow in humans. Tracking values between visits is covered in chronic care and between-visit monitoring.

How do these findings support quality documentation?

Measured insulin resistance, body composition and a scheduled repeat interval are structured findings that document cardiometabolic risk assessment rather than leaving it implied by a gallbladder history. They also make change over time visible in the record. How cardiometabolic measurement maps to reporting programs is described in MIPS and quality reporting.

Is diarrhea common after gallbladder removal?

Chronic diarrhea after cholecystectomy is common enough to ask about. In 1,071 consecutive outpatients referred for chronic diarrhea, 42.7% had bile acid diarrhea, and prior cholecystectomy was one of three predictors of an abnormal result. A third of positives were severe. The practical step is to identify bile acid diarrhea rather than treat the complaint as a nuisance to live with or as presumed overgrowth.

What causes diarrhea after cholecystectomy?

The evidence favors looking for bile acid diarrhea first, ahead of bacterial overgrowth. In surgical cohorts, cholecystectomy carried the lowest overgrowth rate, 17.1%, against 96.2% after gastrectomy, and positivity peaked in patients whose stones were still in place. Stasis with the organ present carries more risk than its absence. Repeating antibiotics after negative breath tests treats an assumption rather than a diagnosis.

How is bile acid diarrhea diagnosed in the United States?

Through gastroenterology. The scan used in the 1,071-patient cohort is not available here, so its prevalence transfers but its diagnostic route does not. Referral for the bile acid assessment available locally is the practical step, ahead of any empiric antibiotic for overgrowth, which needs a positive breath test as its trigger. None of these investigations is a Measura test.

Build metabolic screening into the workup

Learn how the Measura protocol adds laboratory and body composition measurement for patients whose gallbladder history flags metabolic risk.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Lim, S. J., Gracie, D. J., Kane, J. S., Mumtaz, S., Scarsbrook, A. F., Chowdhury, F. U., Ford, A. C., & Black, C. J. (2019). Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: a follow-up study. Neurogastroenterology and Motility, 31(9), e13666. https://doi.org/10.1111/nmo.13666
Kim, Y. J., Paik, C. N., Jo, I. H., Kim, D. B., & Lee, J. M. (2021). Serum gastrin predicts hydrogen-producing small intestinal bacterial overgrowth in patients with abdominal surgery: a prospective study. Clinical and Translational Gastroenterology, 12(1), e00291. https://doi.org/10.14309/ctg.0000000000000291
Kim, D. B., Paik, C. N., Song, D. S., Kim, Y. J., & Lee, J. M. (2018). The characteristics of small intestinal bacterial overgrowth in patients with gallstone diseases. Journal of Gastroenterology and Hepatology, 33(8), 1477-1484. https://doi.org/10.1111/jgh.14113
Cahill, C. J., Pain, J. A., & Bailey, M. E. (1987). Bile salts, endotoxin and renal function in obstructive jaundice. Surgery, Gynecology & Obstetrics, 165(6), 519-522. https://pubmed.ncbi.nlm.nih.gov/3120329/
Thompson, J. N., Cohen, J., Blenkharn, J. I., McConnell, J. S., Barr, J., & Blumgart, L. H. (1986). A randomized clinical trial of oral ursodeoxycholic acid in obstructive jaundice. British Journal of Surgery, 73(8), 634-636. https://doi.org/10.1002/bjs.1800730819
Rudic, J. S., Poropat, G., Krstic, M. N., Bjelakovic, G., & Gluud, C. (2012). Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews, 12(12), CD000551. https://doi.org/10.1002/14651858.CD000551.pub3
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., Abergel, A., Debette-Gratien, M., Larrey, D., Roux, O., Bronowicki, J. P., Boursier, J., de Ledinghen, V., Heurgue-Berlot, A., Nguyen-Khac, E., … Poupon, R. (2018). A placebo-controlled trial of bezafibrate in primary biliary cholangitis. New England Journal of Medicine, 378(23), 2171-2181. https://doi.org/10.1056/NEJMoa1714519
Kars, M., Yang, L., Gregor, M. F., Mohammed, B. S., Pietka, T. A., Finck, B. N., Patterson, B. W., Horton, J. D., Mittendorfer, B., Hotamisligil, G. S., & Klein, S. (2010). Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes, 59(8), 1899-1905. https://doi.org/10.2337/db10-0308
Shahsavari, K., Ardekani, S. S., Ardekani, M. R. S., Esfahani, M. M., Kazemizadeh, H., Jamialahmadi, T., Iranshahi, M., Khanavi, M., & Hasanpour, M. (2025). Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury. BMC Complementary Medicine and Therapies, 25(1), 134. https://doi.org/10.1186/s12906-025-04886-y